197 related articles for article (PubMed ID: 29123424)
21. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
[TBL] [Abstract][Full Text] [Related]
22. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
23. Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study.
Yoon JH; Kim SE; Cho SH; Kim GA; Park Y; Park JW; Kang SH; Lee YS; Kim JH
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629725
[No Abstract] [Full Text] [Related]
24. Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis.
Sahakyan Y; Lee-Kim V; Bremner KE; Bielecki JM; Krahn MD
J Viral Hepat; 2021 May; 28(5):739-754. PubMed ID: 33556225
[TBL] [Abstract][Full Text] [Related]
25. Comparison of clinical outcomes and impact of SVR in American and Chinese patients with chronic hepatitis C.
Rao H; Liu H; Wu E; Yang M; Feng B; Lin A; Fei R; Fontana RJ; Wei L; Lok AS
JHEP Rep; 2020 Aug; 2(4):100136. PubMed ID: 32715286
[TBL] [Abstract][Full Text] [Related]
26. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Nahon P; Bourcier V; Layese R; Audureau E; Cagnot C; Marcellin P; Guyader D; Fontaine H; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Leroy V; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Dharancy S; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Zucman D; Di Martino V; Thibaut V; Salmon D; Ziol M; Sutton A; Pol S; Roudot-Thoraval F;
Gastroenterology; 2017 Jan; 152(1):142-156.e2. PubMed ID: 27641509
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy.
Ogasawara N; Saitoh S; Akuta N; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Suzuki F; Suzuki Y; Arase Y; Ikeda K; Kumada H
Hepatol Res; 2019 Dec; 49(12):1441-1450. PubMed ID: 31373093
[TBL] [Abstract][Full Text] [Related]
28. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
[TBL] [Abstract][Full Text] [Related]
29. Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C.
Hedenstierna M; Nangarhari A; Weiland O; Aleman S
Clin Infect Dis; 2016 Sep; 63(6):723-9. PubMed ID: 27282709
[TBL] [Abstract][Full Text] [Related]
30. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
31. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
[TBL] [Abstract][Full Text] [Related]
32. Five-year follow-up of sustained virological response with hepatitis C infection after direct-acting antiviral therapy: A single-center retrospective study.
Li M; Li Y; Zhang Y; Wang X; Lin C
Medicine (Baltimore); 2024 Feb; 103(7):e37212. PubMed ID: 38363923
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
34. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence.
Nuño Solinís R; Arratibel Ugarte P; Rojo A; Sanchez Gonzalez Y
Infect Dis Ther; 2016 Dec; 5(4):491-508. PubMed ID: 27783223
[TBL] [Abstract][Full Text] [Related]
35. Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.
Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():327-34. PubMed ID: 27051280
[TBL] [Abstract][Full Text] [Related]
36. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C.
Na SK; Song BC
Clin Mol Hepatol; 2019 Sep; 25(3):234-244. PubMed ID: 30661334
[TBL] [Abstract][Full Text] [Related]
37. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
[TBL] [Abstract][Full Text] [Related]
38. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C.
Ogawa E; Chien N; Kam L; Yeo YH; Ji F; Huang DQ; Cheung R; Nguyen MH
JAMA Intern Med; 2023 Feb; 183(2):97-105. PubMed ID: 36508196
[TBL] [Abstract][Full Text] [Related]
39. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response.
Peleg N; Issachar A; Sneh Arbib O; Cohen-Naftaly M; Harif Y; Oxtrud E; Braun M; Leshno M; Barsheshet A; Shlomai A
J Viral Hepat; 2019 Nov; 26(11):1257-1265. PubMed ID: 31243878
[TBL] [Abstract][Full Text] [Related]
40. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
